Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy

Cancer

Volumn 94, Issue 4, 2002, Pages 987-996

  Raj, Ganesh V ^a   Partin, Alan W ^b   Polascik, Thomas J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Biochemical progression; Capromab pendetide; ProstaScint; Prostate specific antigen; Radical prostatectomy; Recurrence

Indexed keywords

CAPROMAB PENDETIDE IN 111; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SCINTISCANNING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; HUMAN; IMMUNOSCINTIGRAPHY; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIOISOTOPE DISTRIBUTION;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CARCINOMA; FOLLOW-UP STUDIES; HUMANS; INDIUM RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0037083675     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10337     Document Type: Article

References (45)

1. PSA following anatomical radical retropubic prostatectomy: Patterns of recurrence and cancer control
2. Natural history of progression after PSA elevation following radical prostatectomy
3. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate
4. Prostate specific antigen: A decade of discovery - What we have learned and where we are going
5. Comparison of serum PSMA, PSA levels with results of cytogen-356 ProstaScint scanning in prostatic cancer patients
6. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy
7. Staging of prostate cancer: Results of Radiology Diagnostic Oncology Group project comparison of three MR imaging techniques
8. Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy
9. Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen: Positron emission tomography and biopsy correlation
10. Capromab pendetide imaging of prostate cancer
11. 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence
12. 111In-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy
13. 111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy
14. 111 capromab pendetide
15. Radiolabeled monoclonal antibody indium 111-labeled CYT-356 localizes extraprostatic recurrent carcinoma after prostatectomy
16. Indium-111 capromab pendetide (capromab pendetide) imaging to detect recurrent and metastatic prostate cancer
17. 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients
18. Immunoscintigraphy in patients with colorectal, ovarian, and prostate cancer
19. Preliminary imaging results using In-111 labeled CYT-356 (ProstaScint®) in the detection of recurrent prostate cancer
20. Expression of prostate-specific membrane antigen in normal, benign and malignant prostate tissues
21. 111Incapromab pendetide: Evaluation before definitive therapy in patients with prostate cancer
22. Clinical applications of radioimmunoscintigraphy with prostate-specific antibodies for prostate cancer
23. Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer
24. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer
25. ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: Analysis of 136 scans of 100 patients
26. Serum PSA after anatomical radical prostatectomy: The Johns Hopkins experience after 10 years
27. Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy
28. Evaluation of serum prostate specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastasis
29. Prostate cancer and prostate bed SPECT imaging with ProstaScint®: Semi-quantitative correlation with prostatic biopsy results
30. Prostate cancer abdominal metastases detected with In-111 capromab pendetide
31. Radioimmunoguided surgery using indium-111 capromab pendetide (ProstaScint) to diagnose supraclavicular metastasis from prostate cancer
32. Evaluation of agreement rates between radionuclide bone scintigraphy and radioimmunoscintigraphy with indium111-capromab pendetide (ProstaScint) in patients with rising PSA after definitive prostate cancer treatment
33. The role of computerized tomography, magnetic resonance imaging, bone scan, and monoclonal antibody nuclear scan for prognosis prediction in prostate cancer
34. Evaluation of prostate cancer patients receiving multiple staging tests, including ProstaScint scintiscans
35. Utilization of polymerase chain reaction technology in the detection of solid tumors
36. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update
37. Use of radioimmunoscintigraphy with indium111-labeled CYT-356 (ProstaScint) scan for evaluation of patients for salvage brachytherapy
38. Followup ProstaScint scans verify detection of occult soft-tissue recurrence after failure of primary prostate cancer therapy
39. Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: The first 10 years
40. Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer
41. PSA based review of adjuvant and salvage radiation therapy vs. observation in postoperative prostate cancer patients
42. Prostate specific antigen only progression of prostate cancer
43. Capromab pendetide. A review of its use as an imaging agent in prostate cancer
44. Monoclonal antibody imaging of recurrent and metastatic prostate cancer
45. Radioimmunoguided imaging of prostate cancer foci with histopathological correlation